SGLT-2 inhibitors reduce cardiovascular risk among patients with chronic kidney disease

Group of the scientists working at the laboratory

SGLT-2 inhibitors, a type of diabetes medicine, decreased cardiovascular risk among adults with chronic kidney disease, according to late-breaking research presented today at the American Heart Association’s Scientific Sessions 2022.

Rosuvastatin vastly superior to six common heart health supplements

Previous article

Children exposed to air pollution in early years more likely to develop food allergies

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in News